Accuray Incorporated (NASDAQ:ARAY) shot up 6.2% during trading on Wednesday . The company traded as high as $4.35 and last traded at $4.30. 779,646 shares traded hands during trading, an increase of 4% from the average session volume of 747,021 shares. The stock had previously closed at $4.05.
A number of research firms recently commented on ARAY. BidaskClub lowered Accuray from a “hold” rating to a “sell” rating in a research report on Saturday. ValuEngine upgraded Accuray from a “sell” rating to a “hold” rating in a research report on Friday, May 18th. Royal Bank of Canada set a $6.00 price target on Accuray and gave the stock a “hold” rating in a research report on Tuesday, April 10th. Finally, Zacks Investment Research lowered Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, March 27th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Accuray has an average rating of “Hold” and a consensus target price of $7.21.
The stock has a market capitalization of $329.71 million, a P/E ratio of -11.94 and a beta of 1.65. The company has a quick ratio of 0.97, a current ratio of 1.62 and a debt-to-equity ratio of 3.00.
Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Monday, April 30th. The medical equipment provider reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.05). The business had revenue of $99.83 million for the quarter, compared to the consensus estimate of $98.18 million. Accuray had a negative return on equity of 52.91% and a negative net margin of 7.00%. equities analysts forecast that Accuray Incorporated will post -0.29 EPS for the current year.
In other Accuray news, CEO Joshua Levine sold 8,675 shares of the company’s stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $4.65, for a total transaction of $40,338.75. Following the transaction, the chief executive officer now owns 1,426,753 shares of the company’s stock, valued at approximately $6,634,401.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 14,257 shares of company stock worth $66,295. Company insiders own 3.90% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Two Sigma Advisers LP lifted its holdings in Accuray by 15.4% during the 4th quarter. Two Sigma Advisers LP now owns 148,930 shares of the medical equipment provider’s stock worth $640,000 after buying an additional 19,900 shares in the last quarter. Sei Investments Co. acquired a new position in Accuray during the 1st quarter worth $107,000. Goldman Sachs Group Inc. lifted its holdings in Accuray by 22.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 126,726 shares of the medical equipment provider’s stock worth $545,000 after buying an additional 23,189 shares in the last quarter. Swiss National Bank lifted its holdings in Accuray by 18.8% during the 4th quarter. Swiss National Bank now owns 154,800 shares of the medical equipment provider’s stock worth $666,000 after buying an additional 24,500 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Accuray by 2.5% during the 1st quarter. Northern Trust Corp now owns 1,027,899 shares of the medical equipment provider’s stock worth $5,139,000 after buying an additional 25,184 shares in the last quarter. 85.45% of the stock is currently owned by hedge funds and other institutional investors.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.